TAP Biosystems' First Installation of ambr 48 System at Leading European Pharma

The system will assist in the prediction of antibody-expressing cell line behavior in large-scale bioreactors.

The European pharmaceutical company purchased the system after performing an on-site evaluation of ambr using their antibody-expressing CHO cell lines. The system closely duplicates bioreactor characteristics at microscale (10 mL-15 mL working volume) and was chosen after scalability of culture performance between ambr, laboratory and manufacturing scale bioreactors was demonstrated by the process development scientists.

The ambr 48 investigates the effects of 48 combinations of cell line and culture conditions. The system enables testing of up to four different temperature and stirrer speeds in a single real-time run, lowering operator time compared to similar experiments in lab scale bioreactors.

Dr. Ralph von Strandmann, TAP Biosystems' European sales manager explained: "With the increasing interest in developing biosimilars and antibody drugs in Europe, progressive pharma companies in this region recognize that our ambr technology can provide a substantial competitive advantage in reducing time to trial."

Dr. von Strandmann added: "We are pleased that this leading European pharma has chosen the ambr 48 system to help select optimum clones and culture conditions. Their confidence shows that other biopharm companies looking to shorten their therapeutic antibody development timelines can also benefit from accessing the ambr technology."

Related Links:
TAP Biosystems